Urinary levels of nuclear matrix protein 22 in patients with urinary diversion

Urothelial bladder cancer: biomarkers for detection and screening

“…NMP22 is generally more sensitive than cytology for low‐grade tumours, but is equivalent to cytology at diagnosing high‐grade tumours. NMP22 is approved by the USA Food and Drug Administration (FDA) for use in the initial diagnosis of bladder cancer and for surveillance, but it is not useful in patients with urinary diversions, due to high rates of false positivity [12]. The NMP22 BladderChek is currently approved for in home use in the USA by prescription, but there is an intention to obtain FDA approval to market the test directly to consumers as an over‐the‐counter product in the USA.…”

Urine‐based Biomarkers

“…157 However, the sensitivity and specificity of NMP22, reported by Grossman et al, were 56% and 85%, respectively, compared to 16% and 99% for cytology. 163 A nomogram has been developed to better predict the probability of urothelial cancer recurrence and progression using the NMP22 test. NMP22 was effective at predicting tumor status at followup cystoscopy.…”